In patients with renal cell carcinoma (RCC), the appearance of positive surgical margin (PSM) has demonstrated a connection with higher risk of cancer-specific mortality (CSM) and recurrence. Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM. A recent study from Cesare Saitta, MD, and colleagues sought to determine the effects of PSM on the oncological outcomes of patients with nonmetastatic RCC undergoing treatment with adjuvant or neoadjuvant systemic therapy. ...
Localized Renal Cell Carcinoma
Advertisement
Latest News
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
Advertisement
Knowledge Hub Spotlight
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Advertisement
Advertisement
Latest News
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
The trial evaluated the data of treatment-naïve patients who underwent RP and received apalutamide as well as ADT.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
